Oncology
Natera is committed to oncology patients by optimizing therapy decisions from diagnosis to survivorship
Natera is committed to oncology patients by optimizing therapy decisions from diagnosis to survivorship
Natera
Natera is a global leader in cell-free DNA (cfDNA) testing, focusing on oncology, women's health, and organ health. The company strives to make personalized genetic testing a standard part of healthcare, enabling earlier and more targeted interventions that lead to longer and healthier lives. Natera's mission is to empower healthcare providers with accurate and reliable information to inform patient care decisions. With its innovative cfDNA technology, the company aims to transform the way healthcare is delivered by providing actionable insights that can help prevent diseases, detect them at an early stage, and guide treatment plans. By combining cutting-edge technology with expert analysis, Natera aims to make a significant impact on healthcare outcomes and improve patient lives.
Natera Oncology Testing Solutions
At Natera, we are dedicated to empowering oncology patients with cutting-edge testing solutions that optimize therapy decisions from diagnosis to survivorship. Our suite of innovative tests offers actionable insights into cancer management, helping patients and clinicians make informed decisions.
Our Comprehensive Testing Portfolio
Our oncology portfolio includes three key tests designed to provide critical information about cancer status and treatment options:
- Signatera: A tumor-informed molecular residual disease (MRD) test that assesses treatment response and monitors for recurrence. Ideal for use after surgery to evaluate the need for adjuvant chemotherapy.
- Altera: A comprehensive tumor genomic profiling test that identifies clinically relevant DNA and RNA biomarkers, offering insights into potential treatment options and clinical trials based on the tumor's somatic profile.
- Empower: A hereditary cancer test that uncovers germline mutations associated with various cancers, providing fast insights into familial cancer risks.
Why Choose Natera?
Natera's tests are developed and validated in our CLIA-certified laboratory, ensuring high-quality performance standards. We are CAP accredited and ISO 13485 certified, underscoring our commitment to excellence in laboratory practices.
Key Benefits of Our Tests
- Early detection of cancer recurrence, potentially while it is still resectable, using Signatera.
- Access to a broader range of treatment options through Altera's genomic profiling.
- Identification of hereditary cancer risks with Empower's rapid testing capabilities.
Patient-Centric Approach
We believe in providing support to both patients and clinicians. Our resources include genetic information sessions, pricing and billing guidance, and access to a dedicated patient coordinator. We aim to make the testing process as seamless and informative as possible.
Real-World Impact
With Natera, you are not only receiving state-of-the-art testing but also contributing to ongoing research and real-world data collection that enhances cancer care. Our commitment to innovation and patient support drives us to continually improve our services and solutions.
Connect with Us
For more information on our oncology tests or to schedule a consultation, please reach out to our patient services team or visit our website. Together, we can navigate the journey of cancer treatment with confidence.
